134 related articles for article (PubMed ID: 12723458)
1. Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.
Hayes KC; Katz MA; Devane JG; Hsieh JT; Wolfe DL; Potter PJ; Blight AR
J Clin Pharmacol; 2003 Apr; 43(4):379-85. PubMed ID: 12723458
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury.
Hayes KC; Potter PJ; Hsieh JT; Katz MA; Blight AR; Cohen R
Arch Phys Med Rehabil; 2004 Jan; 85(1):29-34. PubMed ID: 14970964
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
Vollmer T; Henney HR
Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.
Blight AR; Henney HR
Clin Ther; 2009 Feb; 31(2):328-35. PubMed ID: 19302905
[TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
Vollmer T; Blight AR; Henney HR
Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury.
Hayes KC; Potter PJ; Hansebout RR; Bugaresti JM; Hsieh JT; Nicosia S; Katz MA; Blight AR; Cohen R
Clin Neuropharmacol; 2003; 26(4):185-92. PubMed ID: 12897638
[TBL] [Abstract][Full Text] [Related]
7. Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.
Smith W; Swan S; Marbury T; Henney H
J Clin Pharmacol; 2010 Feb; 50(2):151-9. PubMed ID: 19966074
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: an open-label study.
Samara E; Winkle P; Pardo P; Henney HR; Way SL; Brown E; Lee A; Blight AR
J Clin Pharmacol; 2014 Jan; 54(1):53-60. PubMed ID: 24150835
[TBL] [Abstract][Full Text] [Related]
9. Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury.
Segal JL; Hayes KC; Brunnemann SR; Hsieh JT; Potter PJ; Pathak MS; Tierney DS; Mason D
J Clin Pharmacol; 2000 Apr; 40(4):402-9. PubMed ID: 10761168
[TBL] [Abstract][Full Text] [Related]
10. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
11. Dalfampridine: a new agent for symptomatic management of multiple sclerosis.
McDonald S; Clements JN
Am J Health Syst Pharm; 2011 Dec; 68(24):2335-40. PubMed ID: 22135060
[TBL] [Abstract][Full Text] [Related]
12. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.
Potter PJ; Hayes KC; Segal JL; Hsieh JT; Brunnemann SR; Delaney GA; Tierney DS; Mason D
J Neurotrauma; 1998 Oct; 15(10):837-49. PubMed ID: 9814639
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial.
Grijalva I; Guízar-Sahagún G; Castañeda-Hernández G; Mino D; Maldonado-Julián H; Vidal-Cantú G; Ibarra A; Serra O; Salgado-Ceballos H; Arenas-Hernández R
Pharmacotherapy; 2003 Jul; 23(7):823-34. PubMed ID: 12885095
[TBL] [Abstract][Full Text] [Related]
14. Effect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteers.
Henney HR; Faust B; Blight AR
Am J Health Syst Pharm; 2011 Nov; 68(22):2148-54. PubMed ID: 22058101
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals.
March B; Cardi T
Expert Opin Investig Drugs; 2009 Dec; 18(12):1807-15. PubMed ID: 19938897
[TBL] [Abstract][Full Text] [Related]
16. Fampridine-SR for multiple sclerosis and spinal cord injury.
Hayes KC
Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
[TBL] [Abstract][Full Text] [Related]
17. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial.
Segal JL; Pathak MS; Hernandez JP; Himber PL; Brunnemann SR; Charter RS
Pharmacotherapy; 1999 Jun; 19(6):713-23. PubMed ID: 10391417
[TBL] [Abstract][Full Text] [Related]
19. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
Korenke AR; Rivey MP; Allington DR
Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term 4-aminopyridine therapy on glucose tolerance and glucokinetics in patients with spinal cord injury.
Segal JL; Thompson JF; Tayek JA
Pharmacotherapy; 2007 Jun; 27(6):789-92. PubMed ID: 17542761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
